Cantargia AB

Cantargia is developing a conceptually new cancer therapy, based on the original discovery that certain leukemia stem cells express a specific cell-surface receptor, whereas corresponding normal hematopoietic stem cells do not express this receptor. This receptor is used as a target for development of a new antibody based therapy. Cantargia uses this receptor, the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for CML.